articleThe Lancet OncologyNov 13, 2017Closed access

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

MMMiguel MartínFAFrankie A. HolmesBEBent EjlertsenSDSuzette DelalogeBMBeverly Moy

Centro de Investigación Biomédica en Red de Cáncer · GEICAM – Spanish Breast Cancer Group · +32 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

588
total citations
FWCI
30.38
Percentile
100%
References
27
Citations per year

Authors

626

Topics & keywords

Topics
Keywords
  • Medicine
  • Neratinib
  • Trastuzumab
  • Internal medicine
  • Breast cancer
  • Oncology
  • Clinical endpoint
  • Placebo
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding